Evidence map›Paper›PMID 41788466›Full record

ReviewAddiction & health2025

A Review of Cardiovascular Diseases in Substance Use Disorders: Current Knowledge and Future Perspectives.

Fatemeh Zarei, Mehrdad Simani, Hasan Rajabi Moghaddam, Amir Ghaderi

Abstract readReview
In one paragraph

Review in Addiction & health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh ZareiStudent Research Committee, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0009-0009-7038-1623
Mehrdad SimaniDepartment of Cardiovascular Medicine, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0002-1100-9989
Hasan Rajabi MoghaddamDepartment of Cardiovascular Medicine, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0003-2252-6794
Amir GhaderiSocial Determinants of Health (SDH) Research Center, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0001-9193-6039

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nowadays, the emergence of new types of substances and the growing prevalence of addiction have made substance use a global challenge for public health. At the same time, the complications of substance use are observed in various physical and psychological dimensions, including a range of acute and chronic cardiovascular diseases. This issue is significant, as many young people are affected by these complications. Therefore, understanding these complications is both important and practical. Methods: Clinical articles related to the acute and chronic cardiovascular effects of the main groups of substances were searched in the PubMed, Web of Science, Scopus, and Google Scholar databases from 2015 to 2025. Findings: Evidence of cardiovascular complications related to the use of major substance groups, including opioids, stimulants, nicotine, caffeine, alcohol, cannabinoids, tranquilizers, and anabolic steroids, has been obtained. Some of this evidence only indicates an increase in risk factors for the disease, while some reports also point to acute and chronic cardiac complications and even cardiorespiratory arrest and death. Conclusion: Given the cardiac complications of substance use, cessation and treatment should be personalized to each patient's circumstances.

Indexed as

Cardiovascular diseasesRisk factorsSubstance-related disorders

Identifiers

PMID41788466
PMCPMC12958368

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.